Journal Mobile Options
Table of Contents
Vol. 49, No. 5, 2005
Issue release date: September–October 2005
Ann Nutr Metab 2005;49:289–295

Non-Alcoholic Fatty Liver Disease in Young Adult Severely Obese Non-Diabetic Patients in South Italy

Colicchio P. · Tarantino G. · del Genio F. · Sorrentino P. · Saldalamacchia G. · Finelli C. · Conca P. · Contaldo F. · Pasanisi F.
Interuniversity Center for Obesity and Eating Disorders, Department of Clinical and Experimental Medicine, Federico II University, Napoli, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aims: In the absence of other causes, obesity increases the risk of liver disease. We evaluated the prevalence and degree of metabolic and hepatic abnormalities associated with non-alcoholic fatty liver disease (NAFLD) in type II–III obesity in a metropolitan area of South Italy. Methods: 187 (81 M, 106 F) young adult non-diabetic obese patients, age range 18–50 years (mean 31.9 ± 8.8), body mass index (BMI) ≧30 (mean 47.5 ± 9.6), consecutively admitted from January 2000 to April 2003 to the Obesity Outpatients Clinic entered into the study. Patients were divided into two groups: (1) BMI 30.0–39.9, and (2) BMI≧40. Ultrasound detected liver steatosis was classified as: (I) mild; (II) moderate, and (III) severe. Results: All patients, except 4, showed a variable degree of steatosis: mild was more frequent among females, severe steatosis present only in grade III obesi ty, with higher prevalence in males than in females (p < 0.001). Mean serum transaminases, in particular alanine aminotrasferase (ALT), increased according to BMI and degree of steatosis. Homeostasis Model Assessment (HOMA) index, ferritin and fibrinogen levels increased with BMI, particularly in severe steatosis. In group 2, patients with BMI≧40 showed a positive correlation between ferritin, aspartate aminotransferase (AST) (r = 0.46, p < 0.018), ALT (r = 0.41, p < 0.036) and gamma-glutamyltransferase (γGT) (r = 0.51, p < 0.007), between serum triglycerides (TG) and AST (r = 0.28, p < 0.036), ALT (r = 0.30, p < 0.02) and between HOMA and ALT (r = 0.30, p < 0.03) and γGT (r = 0.35, p < 0.012). In group 2 patients with severe steatosis the prevalence of metabolic syndrome according to Adult Treatment Panel III (ATP III) was 40%. Conclusion: These data suggest that, in young adult non-diabetic grade III obese patients, fatty liver is always present and strictly related to insulin resistance which, in the presence of severe liver steatosis, is also related to serum ferritin.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Sturm R: Increases in clinically severe obesity in the United States, 1986–2000. Arch Intern Med 2003;163:2146–2148.
  2. Willner IR, Waters B, Raj Patil S, Reuben A, Morelli J, Riely CA: Ninety patients with non-alcoholic steatohepatitis: Insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957–2961.
  3. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–923.
  4. Ogden CL, Flegal K M, Carroll MD, Johnson CL: Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA 2002;288:1728–1732.
  5. Dixon J B, Bhathal PS, O’Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91–100.
  6. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, Antonini TM, Alessandri C: Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 2003;18:588–594.
  7. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373–379.
  8. Mehta K, Van Thiel D H, Shah N, Mobarhan S: Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002;60:289–293.
  9. Third report of the National Cholesterol Education Program Expert Panel (Adult Treatment Panel III), Bethesda, Md: NIH Publ 2001, 01-3670.
  10. Saverymuttu SH, Joseph AEA, Maxwell JA: Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986;292:135.

    External Resources

  11. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F, Croce LS, Paoletti S, de Bernard B, Tiribelli C, Dalla Palma L: Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997;27:108–113.
  12. Osawa H, Mori Y: Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical amplitude. J Clin Ultrasound 1996;24:25–29.
  13. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of eleveted aminotransferase levels in the United States. Am J Gastroenterol 2003;98 :960–967.
  14. Day C, James O: Steatohepatitis – A tale of two ‘hits’ (editorial)? Gastroenterology 1998;114:842–845.
  15. Zanger R, Novak R: Effects of fatty acids and ketone bodies on cytochromes p4502B, 4A, 2E1 expression in primary cultured rat hepatocytes. Arch Biochem Biophys 1997;337:217–224.
  16. Bacon B, O’Neill R, Britton R: Hepatic mitochondrial energy production in rats with chronic iron overload. Gastroenterology 1993;105:1134–1140.
  17. Marceau P, Biron S, Hould F-S, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513–1517.
  18. Sorbi D, Boynton J, Lindor KD: The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating non-alcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1987;82:650–654.

    External Resources

  19. Ferrannini E: Insulin resistance, iron, and the liver. Lancet 2000;355:2181–2182.
  20. Angulo P, Keach J C, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356–1362.
  21. García-Monzón C, Fernández-Bermejo M: A wider view on diagnostic criteria of nonalcoholic steatohepatitis. Gastroenterology 2002;122:840–842.
  22. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, Liddle C, Samarasinghe D, George J: Serum leptin in NASH correlates but not fibrosis: A manifestation of lipotoxicity? Hepatology 2002;36:403–409.
  23. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K: Serum leptin levels in patients with non-alcoholic steatohepatitis. Am J Gastrol 2000;95:3584–3589.
  24. Nakao K, Nakata K, Ohtsubo N, Maeda M, Moriuchi T, Ichikawa T, Hamasaki K, Kato Y, Eguchi K, Yukawa K, Ishii N: Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 2002;97:1796–1801.
  25. Diehl AM: Nonalcoholic steatosis and steatohepatitis. IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol 2002;282:G1–G5.
  26. Nair S, Cope K, Terence R H, Diehl: Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastrol 2001;96:1200–1204.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50